Latest news with #LakeStreetCapital
Yahoo
22-07-2025
- Business
- Yahoo
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition
Aytu BioPharma, Inc. (NASDAQ:AYTU) is one of the best high-return penny stocks to buy now. On July 1, Lake Street Capital Markets initiated coverage on Aytu Biosciences (NASDAQ:AYTU) with a Buy rating and an $8.00 price target, citing strong prospects following its acquisition of EXXUA. Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition A scientist in a lab running tests on a variety of biopharmaceuticals. The antidepressant's unique mechanism reportedly avoids two major side effects common in the category, giving it a competitive edge in a saturated yet underserved market. Lake Street expects EXXUA's rollout to significantly boost Aytu's revenue profile by FY 2027, and believes further stock gains are likely as generic concerns ease and product adoption grows. Aytu BioPharma, Inc. (NASDAQ:AYTU) is a pharmaceutical company that develops and commercializes innovative therapies in the U.S. and globally. Its product lineup includes ADHD treatments like Adzenys XR-ODT and Cotempla XR-ODT, as well as pediatric medications such as Karbinal ER for allergies and fluoride-based multivitamins Poly-Vi-Flor and Tri-Vi-Flor for infants and children. While we acknowledge the potential of AYTU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Associated Press
30-06-2025
- Business
- Associated Press
Lake Street Capital Partners Establishes New Residential Services Platform HighPoint Exterior Home Services by Partnering with Choufani & Bailey Roofing & Restoration
CHICAGO, June 30, 2025 /PRNewswire/ -- Lake Street Capital Partners, LP ('Lake Street Capital Partners' or 'Lake Street Cap'), a Chicago-based private equity firm, is pleased to announce the establishment of Exterior Home Services, LLC, doing business as HighPoint Exterior Home Services ('HighPoint'), a new investment platform focused on roofing and related exterior residential services. In combination with this launch, Lake Street Capital Partners has also completed its majority investment in Choufani & Bailey Roofing & Restoration, LLC ('Choufani & Bailey' or the 'Company'). Choufani & Bailey is a North Carolina based provider of exterior home repair, replacement, and remodeling services. Founded in Wilmington, North Carolina, Choufani & Bailey has established itself as a trusted partner to homeowners, property managers, and HOA organizations in need of critical roofing, gutter, siding, and window repair or replacement. The Company's primary focus is to provide retail services to these customers while also bringing the industry expertise to service any, and all, insurance related work for its customer base. More recently, Choufani & Bailey successfully demonstrated the transferability of its model with the recent expansion to the Raleigh market, bringing its differentiated go-to-market strategy and core focus of delivering exceptional customer service and quality to this strategic growth market. 'We are extremely excited to be partnering with the Lake Street Capital Partners team to support and accelerate the growth plans we are executing on at Choufani & Bailey,' said James Bailey, Co-Founder of Choufani & Bailey. 'James and I were committed to finding a proven growth partner to continue to bring our Company's unique value proposition to more customers across the East Coast, " added Sharbel Choufani, Co-Founder of Choufani & Bailey. 'The opportunity to create a partnership with Justin, Brant, and the rest of the Lake Street Capital team to achieve this goal was a no-brainer.' 'Choufani & Bailey represents the perfect company to launch our new platform, HighPoint Exterior Home Services,' said Brant Wilczek, Managing Director of Lake Street Capital Partners. 'James, Sharbel, and the rest of the Choufani & Bailey team have created tremendous brand equity within their core market. Providing them with the resources and strategic support to continue expanding their presence to other highly attractive markets represented a compelling opportunity for us at Lake Street Cap.' 'This latest transaction demonstrates the continued momentum we are experiencing across the residential services sector at Lake Street Cap,' added Justin Terzo, Managing Partner of Lake Street Capital Partners. 'Home services continue to remain attractive due to its recession resilient nature, untapped organic growth potential within many of the sector's operating companies, and opportunity for strategic regional and national market expansion.' As part of the transaction, Lake Street Capital Partners was represented by Stinson LLP and Miller Cooper & Co., Ltd. Choufani & Bailey was advised by Amdel Associates, Inc. About HighPoint Exterior Home Services HighPoint Exterior Home Services was created in 2025 as a platform focused on local and regional companies providing exceptional roofing and related exterior services to homeowners and property managers. The platform was launched in concert with the investment in Choufani & Bailey, an expert in residential roofing replacement and renovation projects serving the Raleigh and Wilmington, North Carolina markets. For more information on HighPoint Exterior Home Services and Choufani & Bailey, please visit About Lake Street Capital Partners, LP Lake Street Capital Partners, LP ('Lake Street Cap') is a Chicago-based private equity firm focused on making control, significant minority, and co-investments in North American based lower middle market companies across the consumer, services, and distribution sectors. Lake Street Cap seeks to invest in growth-oriented founders and family-owned businesses in search of a strategic and value-added capital partner. Lake Street Cap typically makes equity investments of $5 million to $15 million per transaction. For more information, please visit or contact [email protected]. View original content to download multimedia: SOURCE Lake Street Capital Partners
Yahoo
30-06-2025
- Business
- Yahoo
Lake Street Lowers PowerFleet (AIOT) PT, Keeps Buy Rating
PowerFleet, Inc. (NASDAQ:AIOT) is one of the 10 Best Tech Stocks To Buy Under $5. On May 27, Lake Street Capital Markets lowered the price target for PowerFleet, Inc. (NASDAQ:AIOT) from $11 to $8 but kept a 'Buy' rating. This adjustment came after observations of general market softness, which is affecting PowerFleet, Inc. (NASDAQ:AIOT). However, there have not been any order cancellations reported. A data analyst in front of multiple monitors, highlighting the power of data solutions. Jaeson Schmidt of Lake Street Capital Markets pointed out that the company is facing delays and longer sales cycles. These challenges are expected to be short-term. The analyst also said that tariffs might have a slight impact on PowerFleet, Inc.'s (NASDAQ:AIOT) gross margins. Despite these challenges, Schmidt is still positive about the company's future. He believes PowerFleet, Inc. (NASDAQ:AIOT) can achieve significant cost synergies. In the fiscal year 2025, the company realized $16 million in annual cost synergies. $11 million of these benefits were recognized within the fiscal year 2025. Lake Street Capital Markets expects that these cost-saving measures will continue helping the company. The firm has also adjusted its forecast for fiscal year 2026, expecting a better performance in the second half than previously forecasted. PowerFleet, Inc. (NASDAQ:AIOT) offers AI-powered data solutions to improve mobile asset performance, safety, and sustainability. The company's cloud-based platform, Powerfleet Unity, uses AI, machine learning, and IoT connectivity to deliver important insights across industrial, logistics, and transportation sectors. While we acknowledge the potential of AIOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-06-2025
- Business
- Yahoo
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington's disease. A team of scientists in lab coats studying a microscope, working on developing gene therapy solutions. uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130. If the trials go well and the FDA approves it, Lake Street sees AMT-130 as maybe ClearPoint's first 'meaningful partner asset.' ClearPoint provides disposables valued at almost $20,000 for each AMT-130 infusion, suggesting a significant financial benefit associated with the therapy's effectiveness. The FDA's support might result in the approval by the end of 2026, which would have a big effect on ClearPoint's financial standing and confirm its strategic focus on image-guided neurosurgery and gene therapy delivery. According to Lake Street, this regulatory milestone increases clarity on ClearPoint's contribution to the advancement of clinical-stage gene treatments and provides further assurance regarding the clearance timeline for AMT-130. While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
06-06-2025
- Business
- Associated Press
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the 'Company' or 'Aytu') (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1.50. In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price. The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds to the Company, before deducting underwriters' fees and other offering expenses, are expected to be approximately $14.4 million. The Company intends to use the net proceeds of this offering for general corporate purposes, working capital and general and administrative expenses, and to execute on a transaction that will enable the Company to exclusively commercialize EXXUA™ (gepirone) extended-release tablets, a novel, branded, FDA-approved treatment for major depressive disorder in the United States. Lake Street Capital Markets, LLC is acting as sole book runner in connection with the offering. Maxim Group LLC is acting as lead manager, and Ascendiant Capital Markets, LLC is acting as financial advisor. The securities above are being offered pursuant to a registration statement on Form S-1, as amended, (File No. 333-287728) which was declared effective by the United States Securities and Exchange Commission (the 'SEC') on June 5, 2025, and registration statement on Form S-1MEF filed on June 6, 2025. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at The offering is being made only by means of a prospectus forming part of the effective registration statement. Electronic copies of the prospectus relating to this offering, when available, may also be obtained from Lake Street Capital Markets, LLC, 121 South 8th Street, Suite 1000, Minneapolis, Minnesota 55402, telephone: (612) 326-1305, or email: [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Aytu BioPharma Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as 'anticipate,' 'believe,' 'expects,' 'intends,' 'may,' 'plan,' 'should,' 'subject to,' 'will,' 'would' or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding the timing and completion of the offering and the satisfaction of customary closing conditions related to the offering, the anticipated total gross proceeds from the offering and the planned use of the net proceeds of the offering, including those received from the exercise of the underwriters' option, if any. For such statements, Aytu claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Aytu's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and those factors disclosed in Aytu's filings with the SEC, including its Annual Report on Form 10-K filed on September 26, 2024, and its Quarterly Reports on Form 10-Q. These forward-looking statements represent Aytu's judgment as of the time of this release. Aytu disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law. Contacts for Investors Ryan Selhorn, Chief Financial Officer Aytu BioPharma, Inc. [email protected] Robert Blum or Roger Weiss Lytham Partners [email protected] SOURCE: Aytu BioPharma, Inc. press release
